Glenmark receives acceptance from U.S. FDA for Phase 1/2, first-in-human clinical study of GRC 54276

Glenmark Specialty SA, has received acceptance from the U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas.

Related Keywords

India , ,Drug Administration ,Glenmark Pharmaceuticals ,Medicine Group ,Glenmark Pharmaceuticals Ltd ,Investigational New Drug ,Nikhil Amin ,Glenmark Pharmaceuticals Limited ,Glenmarkpharmaceuticals ,Ine935a01035 ,Glenmarkspecialtysa ,Indapplication ,Usfda ,Grc54276 ,Inhumanclinicalstudy ,